General Information


We are a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. Our cell-free protein synthesis platform enables us to design and produce protein carriers and antigens, the critical building blocks of vaccines, in ways that we believe conventional vaccine technologies currently cannot. Our pipeline includes pneumococcal conjugate vaccine, or PCV, candidates that we believe are the most broad-spectrum PCV candidates currently in development, targeting the $7 billion global pneumococcal vaccine market. Our lead vaccine candidate, VAX-24, is a 24-valent investigational PCV that we expect to advance into clinical trials in the second half of 2021.

Employees: 43
Founded: 2013
Contact Information
Address 353 Hatch Drive, Foster City, CA 94404, US
Phone Number (650) 837-0111
Web Address
View Prospectus: Vaxcyte
Financial Information
Market Cap $794.9mil
Revenues $0 mil (last 12 months)
Net Income $-63.7 mil (last 12 months)
IPO Profile
Symbol PCVX
Exchange NASDAQ
Shares (millions): 15.6
Price range $16.00 - $16.00
Est. $ Volume $250.0 mil
Manager / Joint Managers BofA Securities/ Jefferies/ Evercore
CO-Managers Cantor Fitzgerald/ Needham & Co.
Expected To Trade: 6/12/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change